Intraprostatic targeting

Current Opinion in Urology

Volumn 22, Issue 2, 2012, Pages 97-103

  Ukimura, Osamu ^a   Faber, Kenneth ^a   Gill, Inderbir S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Molecular targeting; MRI; prostate biopsy; prostate cancer; transrectal ultrasound

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR; HEAT SHOCK PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

CANCER DIAGNOSIS; CANCER LOCALIZATION; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HUMAN; MALE; MEDICAL TECHNOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; THREE DIMENSIONAL IMAGING; TRANSRECTAL ULTRASONOGRAPHY; ULTRASOUND;

BIOPSY; CATHETER ABLATION; HUMANS; MALE; MOLECULAR IMAGING; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84856759297     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835017fa     Document Type: Review

References (69)

1. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320.
3. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosisdueto prostate-specific antigen screening: lessonsfrom U.S. prostate cancer incidencetrends. J Natl Cancer Inst 2002; 94:981-990. (Pubitemid 34814727)
4. Master VA,Chi T,Simko JP, et al.The independentimpactofextended pattern biopsy on prostate cancer stage migration. J Urol 2005; 174:1789-1793 (Pubitemid 41546940)
5. SEER stat fact sheets: prostate in Surveillance epidemiology and end results by US National Institute of Health. http://seer.cancer.gov/statfacts/ html/ prost.html [Accessed 10 November 2011]
6. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1984. (Pubitemid 40638368)
7. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006; 24:46-50. (Pubitemid 43097357)
8. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancerwith curative intent: an updateofthe Johns Hopkins experience. J Urol 2007; 178:2359-2364.
9. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the manage-mentofprostate cancer in acontemporarycohort. Cancer 2008; 112:2664-2670. (Pubitemid 351969209)
10. Ukimura O, Hung AJ, Gill IS. Innovations in prostate biopsy strategies for active surveillance and focal therapy. Curr Opin Urol 2011; 21:115-120.
11. Toi A, Neill MG, Lockwood GA, et al.The continuing importance of transrectal ultrasound identification of prostatic lesions. J Urol 2007; 177:516-520. (Pubitemid 46054011)
12. Mitterberger MJ, Aigner F, Horninger W, et al. Comparative efficiency of contrast-enhanced colour Doppler ultrasound targeted versus systematic biopsy for prostate cancer detection. Eur Radiol 2010; 20:2791-2796.
13. Tsutsumi M, Miyagawa T, Matsumura T, et al. Real-time balloon inflation elastography for prostate cancer detection and initial evaluation of clinico-pathologic analysis. AJR Am J Roentgenol 2010; 194:W471-W476.
14. Miyagawa T, Ishikawa S, Kimura T, et al. Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol 2010; 17:855-860.
15. Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010; 183:520-527.
16. Sciarra A, Barentsz J, Bjartell A, et al. Advances in magnetic resonance imaging: howtheyare changing the management of prostate cancer. Eur Urol 2011; 59:962-977.
17. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MRimaging at 3 T for prostate cancer: tumor detection and assessment of aggressive-ness. Radiology 2011; 259:775-784; 2011.
18. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176:2432-2437. (Pubitemid 44665992)
19. Ahmed HU, Kirkham A, Arya M, et al. Isittimetoconsiderarolefor MRI before prostate biopsy? Nat Rev Clin Oncol 2009; 6:197-206.
20. Stamey TA, Mc Neal JM, Wise AM, et al. Secondarycancers in the prostate do not determine PSA biochemical failure in untreated men undergoing radical retropubic prostatectomy. Eur Urol 2001; 39 (Suppl 4):22-23. (Pubitemid 32429649)
21. Wise AM, Stamey TA, Mc Neal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60:264-269. (Pubitemid 34831770)
22. Noguchi M, Stamey TA, Mc Neal JE, et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170(2Pt 1):459-463. (Pubitemid 36870224)
23. Terris MK, Freiha FS, Mc Neal JE, et al. Efficacy of transrectal ultrasound for identification of clinically undetected prostatecancer. JUrol1991; 146:78-83.
24. Terris MK, Mc Neal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992; 148:829-832.
25. Terris MK, Haney DJ,Johnstone IM, et al. Prediction of prostatecancervolume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995; 45:75-80.
26. Ukimura O, Troncoso P, Ramirez EI, et al. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998; 159:1251-1259. (Pubitemid 28172808)
27. Mazaheri Y, Hricak H, Fine SW, et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology 2009; 252:449-457.
28. Park H, Meyer CR, Wood D, et al. Validation of automatic target volume definition asdemonstratedfor11C-choline PET/CTof human prostatecancer using multimodalityfusiontechniques.Acad Radiol 2010; 17:614-623.
29. Chen ME, Troncoso P, Johnston DA, et al. Optimization of prostate biopsy strategy using computer based analysis. J Urol 1997; 158:2168-2175. (Pubitemid 27481351)
30. Chen ME,Johnston DA,Tang K, et al. Detailed mapping of prostatecarcinoma foci: biopsy strategy implications. Cancer 2000; 89:1800-1809.
31. Mc Neal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12:897-906. (Pubitemid 19011040)
32. Kawakami S, Okuno T, Yonese J, et al. Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol 2007; 51:675-682.
33. Djavan B, Margreiter M. Biopsy standards for detection of prostate cancer. World J Urol 2007; 25:11-17.
34. Bostwick DG, Waters DJ, Farley ER, et al. Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration; Florida; 24 February 2006.
35. Eggener SE, Scardino PT, Carroll PR, et al. International Task Force on Prostate Cancer and the Focal Lesion Paradigm. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007; 178:2260-2267. (Pubitemid 350052204)
36. Ukimura O, Abreu A, Hung A, et al. Role of TRUS-visibility of cancer in the selection of patients for focal therapy of prostate cancer [abstract 21]. In the 4th International Symposium on Focal therapy and Imaging in Prostate and Kidney Cancer; 26-27 May 2011; Noordwijk, Netherland
37. Braeckman J, Autier P, Soviany C, et al. The accuracy of transrectal ultra-sonography supplemented with computer-aided ultrasonography for detect-ing small prostate cancers. BJU Int 2008; 102:1560-1565.
38. Pallwein L, Mitterberger M, Pelzer A, et al. Ultrasound of prostate cancer: recent advances. Eur Radiol 2008; 18:707-715. (Pubitemid 351447775)
39. Trabulsi EJ, Sackett D, Gomella LG, et al. Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer. Urology 2010; 76:1025-1033.
40. Aigner F, Pallwein L, Junker D, et al. Value of real-time elastography targeted biopsy for prostate cancer detection in men with prostate specific antigen 1.25ng/ml or greater and 4.00ng/ml or less. J Urol 2010; 184:913-917.
41. Suzuki R, Namai E, Oda Y, et al. Cancergene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 2010; 142:245-250.
42. Zolochevska O, Xia X, Williams BJ, et al. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther 2011; 22:1537-1550.
43. Suzuki R, Takizawa T, Negishi Y, et al. Effective gene delivery with novel liposomal bubbles and ultrasonic destruction technology. Int J Pharm 2008; 354:49-55.
44. Kahn T, Bürrig K, Schmitz-Dräger B, et al. Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology 1989; 173:847-851. (Pubitemid 20007231)
45. Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66.
46. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186:1818-1824.
47. Puech P, Betrouni N, Makni N, et al. Computer-assisted diagnosisofprostate cancer using DCE-MRI data: design, implementation and preliminary results. Int J Comput Assist Radiol Surg 2009; 4:1-10.
48. Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic reso-nance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 2011; 21:616-626.
49. Hata N, Jinzaki M, Kacher D, et al. MR imaging-guided prostate biopsy with surgical navigation software: device validation and feasibility. Radiology 2001; 220:263-268. (Pubitemid 32577996)
50. Franiel T, Stephan C, Erbersdobler A, et al. Areas suspicious for prostate cancer: MR-guided biopsy in patientswith at least onetransrectal US-guided biopsy with a negative finding - multiparametric MR imaging for detection and biopsy planning. Radiology 2011; 259:162-172.
51. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ ultrasoundfusion guided prostate biopsy improvescancerdetectionfollowing transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281-1285.
52. Baumann M, Mozer P, Daanen V, et al. Towards 3D ultrasound image based softtissuetracking: atransrectal ultrasound prostate imagealignmentsystem. Med Image Comput Comput Assist Interv 2007; 10:26-33.
53. Baumann M, Mozer P, Daanen V, et al. Prostate biopsy tracking with deformation estimation. Med Image Anal 2011 (in press).
54. Ukimura O, Desai M, Palmer S, et al. Accuracy of 3D elastic registration system of prostate biopsy location by real-time 3D TRUS guidance with MR/TRUS image fusion: Pilot phantom study. J Urol 2012 (in press)
55. Natarajan S, Marks LS, Margolis DJ, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol 2011; 29:334-342.
56. Jadvar H. Prostate cancer: PETwith 18F-FDG, 18F- or 11C-acetate, and 18F-or 11C-choline. J Nucl Med 2011; 52:81-89.
57. Bouchelouche K, Tagawa ST, Goldsmith SJ, et al. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 2011; 41: 29-44.
58. Grenier N, Sardanelli F, Becker CD, et al. Development of molecular imaging in the European radiological community. Eur Radiol 2009; 19:533-536.
59. Katsogiannou M, Peng L, Catapano CV, et al. Active-targeted nanotherapy strategies for prostate cancer. Curr Cancer Drug Targets 2011 (in press). An overview of new strategies for prostate cancer active-targeting nanotherapeutics.
60. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanopar-ticles. Proc Natl Acad Sci U S A 2008; 105:17356-17361.
61. Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009; 10:118-125.
62. Weng J, Wang J, Cai Y, et al. Increased expression of prostate-specific G-protein coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 2005; 113:811-818. (Pubitemid 40101264)
63. Neuhaus EM, Zhang W, Gelis L, et al. Activation of an olfactory receptor inhibits proliferation of prostatecancercells. J Biol Chem 2009; 284:16218-16225.
64. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59:1152-1159. (Pubitemid 29135980)
65. Schroeder RP, de Visser M, van Weerden WM, et al. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer 2010; 126:2826-2834.
66. Berger R, Lin DI, Nieto M, et al. Androgen dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res 2006; 66:5723-5728. (Pubitemid 43927125)
67. Perez SA, Kallinteris NL, Bisias S, et al. Resultsfroma phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptidevaccine in patientswith prostate cancer. Clin Cancer Res 2010; 16:3495-3506.
68. Rocchi P, Jugpal P, So A, et al. Small interference RNA targeting heat shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006; 98:1082-1089. (Pubitemid 44536463)
69. Tan SS, Ahmad I, Bennett HL, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70- Hsp90 client proteins and castrate-resis-tant prostate cancer. J Pathol 2011; 223:81-87.